
    
      Patients with hepatocellular carcinoma seen at Lombardi Cancer Center were evaluated for the
      eligibility of this study.

      The Georgetown Lombardi Comprehensive Cancer Center was responsible for the data and safety
      monitoring of this trial. As this study is an investigator initiated study Phase II study
      utilizing a non-FDA approved drug for which the PI held the IND it was considered a high risk
      study which had real-time monitoring by the PI and study team and quarterly reviews by the
      LCCC Data and Safety Monitoring Committee (DSMC).
    
  